ADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering

ADARx Pharmaceuticals closed the full exercise of the underwriters' option in its IPO, with 3,937,500 additional shares sold at $17.00 per share. The exercise brings total IPO shares to 30,187,500 and aggregate gross proceeds to approximately $513.2 million before underwriting discounts and expenses. Including AbbVie's purchase of 5,255,542 shares in a concurrent private placement, combined gross proceeds reach approximately $602.5 million — a notably strong debut for the late-stage siRNA biotech.

•24d ago

ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

ADARx Pharmaceuticals priced an upsized IPO of 26,250,000 shares at $17.00 per share, expecting approximately $446.3 million in gross proceeds. Shares begin trading on Nasdaq under the ticker ADRX on September 25, 2026, with the offering expected to close September 28. Underwriters hold a 30-day option for up to 3,937,500 additional shares. AbbVie agreed to purchase up to $100.0 million of shares in a concurrent private placement at the same $17.00 price, taking an approximately 4.9% post-closing stake and lifting aggregate gross proceeds to roughly $535.2 million. AbbVie is also an existing siRNA collaboration and license option partner. J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank are lead book-running managers, with LifeSci Capital as an additional book-runner.

•1mo ago